What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?
Maéva Zysman, Fanchon Herman, Léo Grassion, Camille Taillé, Jesus Gonzalez-Bermejo, Marina Guecamburu, Nicolas Roche, Arthur Pavot, Pierre-Olivier Girodet, Arnaud Bourdin, Nicolas Molinari, Patrick Berger, on behalf of the COBRA Study Group · 2024
Read What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients? by Maéva Zysman, Fanchon Herman, Léo Grassion, Camille Taillé, Jesus Gonzalez-Bermejo, Marina Guecamburu, Nicolas Roche, Arthur Pavot, Pierre-Olivier Girodet, Arnaud Bourdin, Nicolas Molinari, Patrick Berger, on behalf of the COBRA Study Group (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11667443.txt.
Description
Maeva Zysman and co-authors size the real-world audience for biologic drugs in lung disease in a 2024 paper. Biologics cut flare-ups in asthma, and trials hint they may help a slice of COPD patients too. But trial entry rules are strict, and nobody knew how many real patients fit them. The team checked a long-running French cohort of over four hundred COPD patients, plus asthma patients with COPD-like features.
Only about one COPD patient in five met the entry rules for at least one biologic on trial. Among asthma patients with COPD features, the eligible share was smaller still, and they were mostly women with worse lung function. Depending on the drug, the true target group ran from about one to eight percent of the whole airway population. The authors temper expectations for these awaited drugs.
Catalog record
| CREATOR | Maéva Zysman, Fanchon Herman, Léo Grassion, Camille Taillé, Jesus Gonzalez-Bermejo, Marina Guecamburu, Nicolas Roche, Arthur Pavot, Pierre-Olivier Girodet, Arnaud Bourdin, Nicolas Molinari, Patrick Berger, on behalf of the COBRA Study Group |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |